期刊
PHARMACOGENOMICS
卷 15, 期 11, 页码 1471-1477出版社
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.90
关键词
CYP3A4; CYP3A4*22; myocardial infarction; pharmacogenetics; rs35599367; statins
资金
- Veni Grant Organization for Scientific Research (NWO) [2001.064]
- Netherlands Heart Foundation (NHS) and TI Pharma [T6-101]
Aim: Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins. Patients & methods: We analyzed the interaction between the *22 minor allele and statin use in the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, using logistic and Cox regression models. Results: In total, 771 MI cases and 6131 controls were included in the analyses. There was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the estimates from both studies were combined (interaction odds ratio: 1.27; 95% CI: 0.73-2.21; p = 0.40 for carriers of the minor T-allele). Conclusion: We found no association of the CYP3A4*22 minor allele (rs35599367) with the effectiveness of statins in reducing MI risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据